Development of therapeutic agents that can bring about effective enhancement of expression of Cisd2 might have potential as a therapeutic strategy for the treatment of fatty liver diseases, thereby preventing subsequent malignant progression to cirrhosis and HCC. Here, CISD2 is linked to fatty liver disease.